What is Hu Kaijun's net worth in 2026?

As of 2026, Hu Kaijun's estimated net worth is $2.952 billion, ranking #1428 among the world's billionaires. The estimate is based on publicly available shareholding data and market prices, updated daily.

How did Hu Kaijun make their money?

Hu Kaijun's wealth primarily comes from Pharmaceuticals, most notably through Pharmaceuticals.

Billionaire Profile

Global Rank

#1428

Hu Kaijun

CEO, Pharmaceuticals

Beijing, China

Real-Time Net Worth

$2.95B

Estimated based on Pharmaceuticals stock value as of September 10, 2026

-1.07% (24h)

Age

Source

Pharmaceuticals

Industry

Healthcare

Citizenship

China

Biography

Hu Kaijun, a prominent figure in China's pharmaceutical industry, is the chairman and CEO of China Grand Enterprises, an investment firm with interests spanning healthcare, real estate, agriculture, and financial services. As of March 25, 2026, his estimated net worth is $3.9 billion. Hu Kaijun's primary wealth source is his stake in Grand Pharmaceutical and Huadong Medicine. His career includes leading China Grand Enterprises, which owns three publicly traded companies: Grand Pharmaceutical, Huadong Medicine, and Grand Industrial Holding. Hu's leadership has driven strategic acquisitions, including the purchase of BlackSwan Vascular in the U.S. in 2023.

AI-Assisted Draft

Not yet reviewed by an editor — how we work

Data Updated

Sep 10, 2026

Report a Correction

Wealth Over Time

Net Worth History

Year	Net Worth	Global Rank	Source
2026	$2.95B	#1428	Forbes Real-Time
2025	$4.30B	—	Forbes List
2024	$4.10B	—	Historical Record
2023	$6.80B	—	Historical Record
2020	$2.30B	—	Historical Record

Portfolio Holdings

Grand Pharmaceutical Group Ltd

HKG:00512•Pharmaceuticals

$13.1B

Holdings Value

Ownership

56%

Hong Kong

Not available employees

In-Depth Profile

Early Life and Career

Information regarding Hu Kaijun's early life and educational background is limited in publicly available sources. However, it is known that he is 64 years old as of March 25, 2026. He is the chairman and CEO of China Grand Enterprises, an investment company.

Rise to Success

Hu Kaijun's success is closely tied to his strategic leadership and investment acumen within China Grand Enterprises. The company has diversified interests, with a primary focus on the healthcare sector. China Grand is the parent company of Grand Pharmaceutical, Huadong Medicine, and Grand Industrial Holding. The acquisition of BlackSwan Vascular for $37.5 million in 2023 was a key move in expanding the company's global footprint.

Key Business Strategies

Hu Kaijun's business strategies include strategic investments and acquisitions, particularly in the healthcare sector. His leadership has seen Grand Pharmaceutical expanding its presence in the international market, acquiring and collaborating with companies to enhance its portfolio. This approach has led to the transfer of medical technologies from European and U.S. startups to China.

Philanthropy

Details about Hu Kaijun's philanthropic activities and the exact amounts are not readily available in the search results.

Career Milestones

2000

Huadong Medicine went public

Hu Kaijun is the chairman of Huadong Medicine

2018

Acquired a stake in Sirtex Medical

A listed arm of China Grand Enterprises acquired a 49% stake in Australia's medical device maker Sirtex

2023

Acquired BlackSwan Vascular

Grand Pharmaceutical agreed to buy 87.5% of U.S.-based vascular drug maker BlackSwan Vascular

Philanthropy & Social Impact

Not Available

$XB

Not Available

Business Philosophy & Leadership

Notable Quotes

"Not Available"

Leadership Principles

Strategic Investment

Focusing on strategic acquisitions and collaborations to expand market presence.

Global Expansion

Expanding the company's global footprint through acquisitions

Controversies & Challenges

2013

Transformation of SOE

Questions raised about the transformation of a state-owned enterprise into China Grand Enterprises through transactions that raised questions about corporate governance and asset valuation

Billionaires Connected to Hu Kaijun

Peers in Healthcare

Thomas Frist Jr & family#69 · $34.8B
Cyrus Poonawalla#81 · $28.7B
Dilip Shanghvi#94 · $26.5B
Zhong Huijuan#149 · $18.4B
Ludwig Merckle#186 · $16.1B
Murali Divi & family#224 · $14.1B

All Healthcare billionaires →

Richest in China

Zhang Yiming#26 · $84.0B
Zhong Shanshan#32 · $59.8B
Ma Huateng#41 · $46.8B
Liang Wenfeng#52 · $39.9B
William Ding#55 · $39.3B

All billionaires from China →

Adjacent Global Ranks

Zhang Lei#1425 · $2.96B
Richard Hayne & family#1426 · $2.95B
Zhang Yuqiang#1427 · $2.95B
Lee Bass#1429 · $2.95B

Full global ranking →

Compare Hu Kaijun

Net Worth Face-off

Hu Kaijun vs Elon Musk

Compare Wealth →

Net Worth Face-off

Hu Kaijun vs Jeff Bezos

Compare Wealth →

Net Worth Face-off

Hu Kaijun vs Mark Zuckerberg

Compare Wealth →

Frequently Asked Questions

What is Hu Kaijun's net worth in 2026?: As of 2026, Hu Kaijun's estimated net worth is $2.952 billion, ranking #1428 among the world's billionaires. The estimate is based on publicly available shareholding data and market prices, updated daily.
How did Hu Kaijun make their money?: Hu Kaijun's wealth primarily comes from Pharmaceuticals, most notably through Pharmaceuticals.
Where is Hu Kaijun from?: Hu Kaijun is from China.
How old is Hu Kaijun?: Hu Kaijun is 64 years old.

Sources & References

Hu Kaijun — Forbes profile — Forbes